Braden Michael Leonard Increases Stake in Adverum Biotechnologies

Summary

Braden Michael Leonard, a major shareholder in Adverum Biotech, purchased 15,209 shares at $4.04 each, totaling $61,444.36, increasing his holdings by 0.55%. Post-transaction, he owns 2,757,526 shares valued at about $11.14 million. Recent purchases included 19,566 shares at $4.38 and 62,341 shares at $4.69. The stock rose 11.2%, now priced at $4.26, with analysts’ mixed ratings and an average target price of $27.83.Market Beat

Impact Analysis

The event is at the company level, focusing on Adverum Biotech. Leonard’s share purchase indicates strong insider confidence, potentially signaling positive future prospects for the company. Despite mixed analyst ratings, the average target price of $27.83 suggests significant growth potential compared to the current price of $4.26. First-order effects include increased investor interest and potential stock price appreciation due to perceived insider confidence. Second-order effects might involve heightened scrutiny and analysis of Adverum’s strategic moves and product pipeline. Investment opportunities could revolve around considering Adverum as a speculative buy, given insider activity and the substantial gap between current stock price and analysts’ target price.Market Beat